SU2C Blog Archive October 2016
Posted on October 21, 2016, 10:15 AMCancer survivor Rodney Bostick shares his #HowIFight story and the one moment he hopes to never forget.
Immunotherapy in early stage lung cancer shows promise in a clinical trial supported in part by SU2C
Posted on October 10, 2016, 4:00 PMCheckpoint inhibition is a form of immunotherapy that releases the anti-cancer function of patients’ own immune cells. It’s transformed the treatment of a number of cancers. Patrick Forde, MBBCh, assistant professor of oncology at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, reported promising data from a study of nivolumab (Opdivo), a checkpoint inhibitor, in early-stage lung cancer at the 2016 Congress of the European Society for Medical Oncology (ESMO) in Copenhagen, Denmark, on Oct. 7.
- SU2C SAC Chair Phillip A. Sharp, PhD, Recognized by AACR for Scientific Leadership
- New Opportunities for Collaboration Through the SU2C Convergence Initiative
- Cancer Taught Me to Live My Best Life
- Taking on the Childhood Cancer Bully
- Helping High Schoolers Find Research and STEM Field Opportunities
- SU2C’s Scientific Partner Reports on Progress in the Struggle Against Cancer
- Tackling the BRCA Gene on The Bold Type
- SU2C’s Research in the Fight Against Glioblastoma and Other Brain Cancers
- Honoring a Loved One Through Fundraising
- How to Become an Empowered Cancer Patient